CN103933060A - 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 - Google Patents
红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 Download PDFInfo
- Publication number
- CN103933060A CN103933060A CN201410171055.9A CN201410171055A CN103933060A CN 103933060 A CN103933060 A CN 103933060A CN 201410171055 A CN201410171055 A CN 201410171055A CN 103933060 A CN103933060 A CN 103933060A
- Authority
- CN
- China
- Prior art keywords
- hps
- hedysamn polysaccharide
- hedysamn
- polysaccharide
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000036541 health Effects 0.000 title claims abstract description 6
- 241000214032 Hedysarum Species 0.000 title abstract 3
- 150000001720 carbohydrates Chemical class 0.000 title abstract 3
- -1 HPS 4 Chemical compound 0.000 claims abstract description 5
- 150000004676 glycans Chemical class 0.000 claims description 66
- 229920001282 polysaccharide Polymers 0.000 claims description 66
- 239000005017 polysaccharide Substances 0.000 claims description 66
- 230000002265 prevention Effects 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 230000001009 osteoporotic effect Effects 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 230000011164 ossification Effects 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000013459 approach Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 17
- 239000011575 calcium Substances 0.000 abstract description 17
- 229910052791 calcium Inorganic materials 0.000 abstract description 17
- 230000037182 bone density Effects 0.000 abstract description 14
- 238000012360 testing method Methods 0.000 abstract description 13
- 210000000988 bone and bone Anatomy 0.000 abstract description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 11
- 101000985500 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) 3-hexulose-6-phosphate synthase 3 Proteins 0.000 abstract description 7
- 101000985497 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) 3-hexulose-6-phosphate synthase 1 Proteins 0.000 abstract description 4
- 210000001672 ovary Anatomy 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 35
- 210000000963 osteoblast Anatomy 0.000 description 18
- 210000000689 upper leg Anatomy 0.000 description 17
- 102100028902 Hermansky-Pudlak syndrome 1 protein Human genes 0.000 description 16
- 102100028716 Hermansky-Pudlak syndrome 3 protein Human genes 0.000 description 11
- 102100028715 Hermansky-Pudlak syndrome 4 protein Human genes 0.000 description 11
- 101000838926 Homo sapiens Hermansky-Pudlak syndrome 1 protein Proteins 0.000 description 11
- 101000985492 Homo sapiens Hermansky-Pudlak syndrome 3 protein Proteins 0.000 description 11
- 101000985501 Homo sapiens Hermansky-Pudlak syndrome 4 protein Proteins 0.000 description 11
- 102000004067 Osteocalcin Human genes 0.000 description 9
- 108090000573 Osteocalcin Proteins 0.000 description 9
- 102000004264 Osteopontin Human genes 0.000 description 9
- 108010081689 Osteopontin Proteins 0.000 description 9
- 230000004072 osteoblast differentiation Effects 0.000 description 9
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 8
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000266851 Hedysarum polybotrys Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000002624 Sp7 Transcription Factor Human genes 0.000 description 2
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000011633 osteoporosis animal model Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410171055.9A CN103933060B (zh) | 2014-04-25 | 2014-04-25 | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410171055.9A CN103933060B (zh) | 2014-04-25 | 2014-04-25 | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103933060A true CN103933060A (zh) | 2014-07-23 |
CN103933060B CN103933060B (zh) | 2016-08-17 |
Family
ID=51181118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410171055.9A Active CN103933060B (zh) | 2014-04-25 | 2014-04-25 | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103933060B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106830350A (zh) * | 2016-12-31 | 2017-06-13 | 新昌县派特普科技有限公司 | 水产养殖的复合水质改良剂及其制备方法 |
CN108892733A (zh) * | 2018-05-25 | 2018-11-27 | 兰州大学 | 一种红芪多糖修饰方法及修饰的红芪多糖的应用 |
CN115364276A (zh) * | 2022-08-19 | 2022-11-22 | 兰州大学第二医院 | 一种含红芪多糖的复合增强型磷酸钙骨水泥及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059152A (zh) * | 2011-12-06 | 2013-04-24 | 封士兰 | 红芪多糖3的分离物及其用途 |
-
2014
- 2014-04-25 CN CN201410171055.9A patent/CN103933060B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059152A (zh) * | 2011-12-06 | 2013-04-24 | 封士兰 | 红芪多糖3的分离物及其用途 |
Non-Patent Citations (2)
Title |
---|
苏开鑫等: "《红芪水提液防治大鼠类固醇性骨质疏松的实验研究》", 《实用中西医结合临床》 * |
赵良功等: "《4种红芪多糖对实验性糖尿病小鼠血糖的影响》", 《JOURNAL OF CHINESE MEDICINAL MATERIALS》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106830350A (zh) * | 2016-12-31 | 2017-06-13 | 新昌县派特普科技有限公司 | 水产养殖的复合水质改良剂及其制备方法 |
CN108892733A (zh) * | 2018-05-25 | 2018-11-27 | 兰州大学 | 一种红芪多糖修饰方法及修饰的红芪多糖的应用 |
CN108892733B (zh) * | 2018-05-25 | 2021-04-30 | 兰州大学 | 一种红芪多糖修饰方法及修饰的红芪多糖的应用 |
CN115364276A (zh) * | 2022-08-19 | 2022-11-22 | 兰州大学第二医院 | 一种含红芪多糖的复合增强型磷酸钙骨水泥及其制备方法和应用 |
CN115364276B (zh) * | 2022-08-19 | 2023-06-09 | 兰州大学第二医院 | 一种含红芪多糖的复合增强型磷酸钙骨水泥及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103933060B (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103251671B (zh) | 一种增加骨密度的含中药的组合物及其制备方法 | |
CN102949710B (zh) | 增加骨密度的药物组合物或保健品及其制备方法 | |
CN102526326B (zh) | 用于治疗绝经后骨质疏松症的中药及其制备方法 | |
CN103933060B (zh) | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 | |
CN103721242A (zh) | 一种药物组合物在预防或治疗骨质疏松中的新用途 | |
CN101239083A (zh) | 女贞子的医药新用途及其药物制剂 | |
CN101485774A (zh) | 治疗骨质疏松的口服液 | |
CN102626463A (zh) | 一种增加骨密度、防治骨质疏松症的天然药物组合物 | |
CN101549177B (zh) | 一种用于脊柱内固定术螺钉的药物涂层及制备和应用 | |
CN102949712A (zh) | 一种治疗肿瘤疾病的中西复合药物 | |
CN111870689A (zh) | 一种纳豆激酶在治疗骨质疏松药物中的应用 | |
CN106806403B (zh) | 一种增加骨密度的中药复方组合物及其制备方法 | |
CN104587456A (zh) | 一种增加骨密度的保健品的制作工艺 | |
CN103919908A (zh) | 一种预防和治疗废用性骨质疏松的药物及其制备方法 | |
CN116212007B (zh) | 一种治疗中期骨折的接骨柔筋中药组合物及其制备方法 | |
CN100459985C (zh) | 当归油在制备治疗更年期综合征和骨质疏松的药物中的应用 | |
CN111991405B (zh) | 莪术二酮联合白果新酸在制备促进骨形成药物中的应用 | |
CN102961518B (zh) | 参仙组合药物制备治疗骨质疏松药物中的应用 | |
US11517602B2 (en) | Traditional Chinese medicine composition for improving bone health and preparation and uses thereof | |
CN107115424A (zh) | 改变酸性体质保钙及清热解毒的中药组合物及制备方法 | |
CN101352480B (zh) | 一种治疗骨质疏松症的中药组合物及其制备方法 | |
CN104758503B (zh) | 一种促进骨折愈合的组合物及其水煎液的制备方法 | |
CN1250239C (zh) | 一种治疗腰痛病的药物及制备方法 | |
KR101386323B1 (ko) | 모자반 추출물을 유효성분으로 함유하는 폐경기후 골다공증의 완화, 예방 또는 치료용 약학조성물 및 이를 포함하는 건강기능식품 | |
CN1498629A (zh) | 一种治疗骨质疏松症的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190423 Address after: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee after: GANSU ZHONGTIAN PHARMACEUTICAL Co.,Ltd. Address before: 730000 No. 222 Tianshui South Road, Chengguan District, Lanzhou, Gansu Patentee before: Lanzhou University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201116 Address after: 748100 North Road, Changan Road, Longxi County, Gansu, Dingxi Patentee after: GANSU ZHONGTIAN JINDAN PHARMACEUTICAL Co.,Ltd. Address before: 748100 North Road, Changan Road, Longxi County, Gansu, Dingxi Patentee before: GANSU ZHONGTIAN PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee after: Gansu Zhijiao Pharmaceutical Co.,Ltd. Country or region after: China Address before: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee before: GANSU ZHONGTIAN JINDAN PHARMACEUTICAL Co.,Ltd. Country or region before: China |